News
-
-
-
-
COMMUNIQUÉ RÉGLEMENTÉ
Successful capital increase for NFL Biosciences with over €3 million raised
NFL Biosciences successfully raises over €3 million in capital increase, securing funds for upcoming Phase 3 clinical trial of NFL-101 and advancing development of NFL-301. New shares to be listed on Euronext Growth Paris on April 16, 2024 -
-
-
-
COMMUNIQUÉ RÉGLEMENTÉ
NFL Biosciences launches a fundraising round for 3 million euros through a capital increase
NFL Biosciences launches a fundraising round for 3 million euros through a capital increase, aiming to support Phase 3 clinical trial for NFL-101 and development of NFL-301 drug candidates -
-